Regal Investment Advisors LLC Cuts Stake in Royalty Pharma plc (NASDAQ:RPRX)

Regal Investment Advisors LLC cut its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 38.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 17,715 shares of the biopharmaceutical company’s stock after selling 11,138 shares during the quarter. Regal Investment Advisors LLC’s holdings in Royalty Pharma were worth $452,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RPRX. Barclays PLC lifted its position in shares of Royalty Pharma by 16.3% in the 3rd quarter. Barclays PLC now owns 308,887 shares of the biopharmaceutical company’s stock worth $8,737,000 after purchasing an additional 43,339 shares during the period. M&T Bank Corp raised its stake in Royalty Pharma by 4.3% in the third quarter. M&T Bank Corp now owns 18,749 shares of the biopharmaceutical company’s stock worth $531,000 after buying an additional 779 shares in the last quarter. Sanctuary Advisors LLC lifted its holdings in Royalty Pharma by 78.9% during the third quarter. Sanctuary Advisors LLC now owns 41,466 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 18,288 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Royalty Pharma during the 3rd quarter valued at $61,000. Finally, Franklin Resources Inc. increased its holdings in shares of Royalty Pharma by 5.0% in the 3rd quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company’s stock valued at $40,705,000 after acquiring an additional 70,130 shares during the period. 54.35% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on RPRX shares. Citigroup restated a “buy” rating on shares of Royalty Pharma in a research note on Friday, March 28th. TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $42.50.

Royalty Pharma Stock Down 0.8 %

Royalty Pharma stock opened at $32.19 on Thursday. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $34.20. The business has a fifty day moving average price of $32.55 and a 200-day moving average price of $29.22. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The stock has a market capitalization of $18.56 billion, a price-to-earnings ratio of 22.20, a PEG ratio of 2.31 and a beta of 0.50.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Equities research analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.